Table 2 Kaplan-Meier survival analysis for overall (OS), disease-free (DFS) and local-recurrence free (LRF) survival relative to gene expressions (n): number of patients
From: Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients
OS means (months) | 95% CI (months) | OS (5 years)% | p-value | |
|---|---|---|---|---|
TRF2 (n) | ||||
High expression (13) | 73.0 | 58.1 – 87.8 | 69.2 | 0.154 |
Low expression (7) | 49.9 | 27.9 – 71.9 | 28.6 | |
Bcl-xL (n) | ||||
High expression (11) | 46.5 | 30.4-62.7 | 27.3 | 0.002* |
Low expression (9) | 86.8 | 77.7-95.9 | 88.9 | |
p53 (n) | ||||
High expression (9) | 48.6 | 29.3-67.9 | 33.3 | 0.02* |
Low expression (11) | 78.1 | 64.2-91.9 | 72.7 | |
DFS means (months) | 95% CI (months) | DFS (5 years)% | p-value | |
TRF2 (n) | ||||
High expression (13) | 70.3 | 53.3 – 87.3 | 69.2 | 0.124 |
Low expression (7) | 43.9 | 21.1 – 66.8 | 28.6 | |
Bcl-xL (n) | ||||
High expression (11) | 41.1 | 23.9-58.4 | 27.3 | 0.003* |
Low expression (9) | 84.8 | 72.0-97.5 | 88.9 | |
p53 (n) | ||||
High expression (9) | 45.8 | 25.7-66 | 33.3 | 0.04* |
Low expression (11) | 73.4 | 55.4-91.2 | 72.7 | |
Local control means (months) | 95% CI (months) | LRF (5 years)% | p-value | |
TRF2 (n) | ||||
High expression (13) | 58.7 | 44.4-72.9 | 76.9 | 0.750 |
Low expression (7) | 54.5 | 32.2-76.9 | 57.1 | |
Bcl-xL (n) | ||||
High expression (11) | 45.4 | 26.4-64.3 | 45.5 | 0.01* |
Low expression (9) | 71.6 | 66.0-77.0 | 88.9 | |
p53 (n) | ||||
High expression (9) | 49.5 | 28.4-70.7 | 55.6 | 0.10 |
Low expression (11) | 43.4 | 30.7-76 | 72.7 |